MUC1 and non-small cell lung carcinoma: The MUC1 tandem repeat non-glycosylated, lipid-encapsulated peptide (BLP25, Tecemotide) administered with chemotherapy to regionally advanced non-small cell lung cancer patients elicited a 10-month survival advantage in an 806 patient subset [15].